|
1
|
Dilly CK and Kahi CJ: Does increased adenoma detection reduce the risk of colorectal cancer, and how good do we need to be? Curr Gastroenterol Rep. 21:92019. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Fabišíková K, Behulová RL and Repiska V: Molecular biomarkers in the diagnostic of patients with colorectal cancer. Neuro Endocrinol Lett. 40:215–221. 2019.PubMed/NCBI
|
|
3
|
Roberts BS, Hardigan AA, Moore DE, Ramaker RC, Jones AL, Fitz-Gerald MB, Cooper GM, Wilcox CM, Kimberly RP and Myers RM: Discovery and validation of circulating biomarkers of colorectal adenoma by high-depth small RNA sequencing. Clin Cancer Res. 24:2092–2099. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Versace VL, Forsyth AD, Vaughan R, Morrice MG and Morphett BJ: Evidence of elevated colorectal cancer and adenoma rates for regional National bowel cancer screening program participants. Aust J Rural Health. 26:63–64. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Zhou H, Shen Z, Zhao J, Zhou Z and Xu Y: Distribution characteristics and risk factors of colorectal adenomas. Zhonghua Wei Chang Wai Ke Za Zhi. 21:678–684. 2018.(In Chinese). PubMed/NCBI
|
|
6
|
Yang B, Mao L, Li Y, Li Q, Li X, Zhang Y and Zhai Z: β-catenin, leucine-rich repeat-containing G protein-coupled receptor 5 and GATA-binding factor 6 are associated with the normal mucosa-adenoma-adenocarcinoma sequence of colorectal tumorigenesis. Oncol Lett. 15:2287–2295. 2018.PubMed/NCBI
|
|
7
|
Lee JK, Jensen CD, Levin TR, Doubeni CA, Zauber AG, Chubak J, Kamineni AS, Schottinger JE, Ghai NR, Udaltsova N, et al: Long-term risk of colorectal cancer and related death after adenoma removal in a large, community-based population. Gastroenterology. 158:884–894.e5. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Lochhead P, Chan AT, Giovannucci E, Fuchs CS, Wu K, Nishihara R, O'Brien M and Ogino S: Progress and opportunities in molecular pathological epidemiology of colorectal premalignant lesions. Am J Gastroenterol. 109:1205–1214. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Dinarvand P, Davaro EP, Doan JV, Ising ME, Evans NR, Phillips NJ, Lai J and Guzman MA: Familial adenomatous polyposis syndrome: An update and review of extraintestinal manifestations. Arch Pathol Lab Med. 143:1382–1398. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Taherian M, Lotfollahzadeh S, Daneshpajouhnejad P and Arora K: Tubular Adenoma. StatPearls. StatPearls Publishing LLC; Treasure Island, FL: 2020
|
|
11
|
Tischoff I and Tannapfel A: Precancerous colorectal tumors. Internist (Berl). 54:691–698. 2013.(In German). View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Nguyen LH, Goel A and Chung DC: Pathways of colorectal carcinogenesis. Gastroenterology. 158:291–302. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Guo Y, Bao Y and Yang W: Regulatory miRNAs in colorectal carcinogenesis and metastasis. Int J Mol Sci. 18:8902017. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Schatoff EM, Leach BI and Dow LE: Wnt signaling and colorectal cancer. Curr Colorectal Cancer Rep. 13:101–110. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Wang L, Li D, Liu Y, Wang Y, Cui J, Cui A and Wu W: Expression of RUNX3 and β-catenin in the carcinogenesis of sporadic colorectal tubular adenoma. Tumour Biol. 35:6039–6046. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Kirchner T and Brabletz T: Patterning and nuclear beta-catenin expression in the colonic adenoma-carcinoma sequence. Analogies with embryonic gastrulation. Am J Pathol. 157:1113–1121. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Kirsanov K, Fetisov T, Lesovaya EA, Maksimova V, Trukhanova L, Antoshina E, Gor'kova T, Morozova O, Safina A, Fleyshman D, et al: Prevention of colorectal carcinogenesis by DNA-binding small-molecule curaxin CBL0137 involves suppression of Wnt signaling. Cancer Prev Res (Phila). 13:53–64. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Lo YH, Noah TK, Chen MS, Zou W, Borras E, Vilar E and Shroyer NF: SPDEF induces quiescence of colorectal cancer cells by changing the transcriptional targets of β-catenin. Gastroenterology. 153:205–218.e8. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Dong J, Wang R, Ren G, Li X, Wang J, Sun Y, Liang J, Nie Y, Wu K, Feng B, et al: HMGA2-FOXL2 axis regulates metastases and epithelial-to-mesenchymal transition of chemoresistant gastric cancer. Clin Cancer Res. 23:3461–3473. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
El Ayachi I, Fatima I, Wend P, Alva-Ornelas JA, Runke S, Kuenzinger WL, Silva J, Silva W, Gray JK, Lehr S, et al: The WNT10B network is associated with survival and metastases in chemoresistant triple-negative breast cancer. Cancer Res. 79:982–993. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Gao X, Dai M, Li Q, Wang Z, Lu Y and Song Z: HMGA2 regulates lung cancer proliferation and metastasis. Thorac Cancer. 8:501–510. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Li XX, Di X, Cong S, Wang Y and Wang K: The role of let-7 and HMGA2 in the occurrence and development of lung cancer: A systematic review and meta-analysis. Eur Rev Med Pharmacol Sci. 22:8353–8366. 2018.PubMed/NCBI
|
|
23
|
Xu L, Du B, Lu QJ, Fan XW, Tang K, Yang L and Liao WL: MiR-541 suppresses proliferation and invasion of squamous cell lung carcinoma cell lines via directly targeting high-mobility group AT-hook 2. Cancer Med. 7:2581–2591. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Mansoori B, Duijf PHG, Mohammadi A, Najafi S, Roshani E, Shanehbandi D, Hajiasgharzadeh K, Shirjang S, Ditzel HJ, Kazemi T, et al: Overexpression of HMGA2 in breast cancer promotes cell proliferation, migration, invasion and stemness. Expert Opin Ther Targets. 1–11. 2020.(Epub ahead of print). PubMed/NCBI
|
|
25
|
Sgarra R, Pegoraro S, Ros G, Penzo C, Chiefari E, Foti D, Brunetti A and Manfioletti G: High mobility group A (HMGA) proteins: Molecular instigators of breast cancer onset and progression. Biochim Biophys Acta Rev Cancer. 1869:216–229. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Cai X, Nie J, Chen L and Yu F: Circ_0000267 promotes gastric cancer progression via sponging MiR-503-5p and regulating HMGA2 expression. Mol Genet Genomic Med. 8:e10932020. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Li W, Li J, Mu H, Guo M and Deng H: MiR-503 suppresses cell proliferation and invasion of gastric cancer by targeting HMGA2 and inactivating WNT signaling pathway. Cancer Cell Int. 19:1642019. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Wang X, Wang J and Wu J: Emerging roles for HMGA2 in colorectal cancer. Transl Oncol. 14:1008942021. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Jiang H, Li Y, Li J, Zhang X, Niu G, Chen S and Yao S: Long noncoding RNA LSINCT5 promotes endometrial carcinoma cell proliferation, cycle, and invasion by promoting the Wnt/β-catenin signaling pathway via HMGA2. Ther Adv Med Oncol. Sep 29–2019.(Epub ahead of print). doi: 10.1177/1758835919874649. View Article : Google Scholar
|
|
30
|
Wend P, Runke S, Wend K, Anchondo B, Yesayan M, Jardon M, Hardie N, Loddenkemper C, Ulasov I, Lesniak MS, et al: WNT10B/β-catenin signalling induces HMGA2 and proliferation in metastatic triple-negative breast cancer. EMBO Mol Med. 5:264–279. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Shia J, Klimstra DS, Bagci P, Basturk O and Adsay NV: TNM staging of colorectal carcinoma: Issues and caveats. Semin Diagn Pathol. 29:142–153. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Barca I, Mignogna C, Donato G and Cristofaro MG: Expression of PLAG1, HMGA1 and HMGA2 in minor salivary glands tumours. Gland Surg. 10:1609–1617. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Zhou Y, Huang Y, Cao X, Xu J, Zhang L, Wang J, Huang L, Huang S, Yuan L, Jia W, et al: WNT2 promotes cervical carcinoma metastasis and induction of epithelial-mesenchymal transition. PLoS One. 11:e01604142016. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Zou Y, Zhang Y, Church J and Liu X: Comparison of β-Catenin and LEF1 immunohistochemical stains in desmoid-type fibromatosis and its selected mimickers, with unexpected finding of LEF1 positivity in scars. Appl Immunohistochem Mol Morphol. 26:648–653. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Chen H, Gao J, Du Z, Zhang X, Yang F and Gao W: Expression of factors and key components associated with the PI3K signaling pathway in colon cancer. Oncol Lett. 15:5465–5472. 2018.PubMed/NCBI
|
|
36
|
Zhao H, Cao Y, Wang G and Luo Z: Expression of FOXC2, PinX1, Ki-67 and Cyclin D1 in cutaneous cell carcinoma. Oncol Lett. 14:635–638. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Valenta T, Hausmann G and Basler K: The many faces and functions of β-catenin. EMBO J. 31:2714–2736. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Zhu J, Wang H, Xu S and Hao Y: Clinicopathological and prognostic significance of HMGA2 overexpression in gastric cancer: A meta-analysis. Oncotarget. 8:100478–100489. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Ma Y, Zheng W, Chen H, Shao X, Lin P, Liu X, Li X and Ye H: Glucosamine promotes chondrocyte proliferation via the Wnt/β-catenin signaling pathway. Int J Mol Med. 42:61–70. 2018.PubMed/NCBI
|
|
41
|
Doumpas N, Lampart F, Robinson MD, Lentini A, Nestor CE, Cantù C and Basler K: TCF/LEF dependent and independent transcriptional regulation of Wnt/β-catenin target genes. EMBO J. 38:e988732019. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Testa U, Pelosi E and Castelli G: Colorectal cancer: Genetic abnormalities, tumor progression, tumor heterogeneity, clonal evolution and tumor-initiating cells. Med Sci (Basel). 6:312018.PubMed/NCBI
|
|
43
|
Wei R, Shang Z, Leng J and Cui L: Increased expression of high-mobility group A2: A novel independent indicator of poor prognosis in patients with esophageal squamous cell carcinoma. J Cancer Res Ther. 12:1291–1297. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Binabaj MM, Soleimani A, Rahmani F, Avan A, Khazaei M, Fiuji H, Soleimanpour S, Ryzhikov M, Ferns GA, Bahrami A and Hassanian SM: Prognostic value of high mobility group protein A2 (HMGA2) over-expression in cancer progression. Gene. 706:131–139. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Yang S, Gu Y, Wang G, Hu Q, Chen S, Wang Y and Zhao M: HMGA2 regulates acute myeloid leukemia progression and sensitivity to daunorubicin via Wnt/β-catenin signaling. Int J Mol Med. 44:427–436. 2019.PubMed/NCBI
|
|
46
|
Sebio A, Kahn M and Lenz HJ: The potential of targeting Wnt/β-catenin in colon cancer. Expert Opin Ther Targets. 18:611–615. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Prossomariti A, Piazzi G, Alquati C and Ricciardiello L: Are Wnt/β-Catenin and PI3K/AKT/mTORC1 distinct pathways in colorectal cancer? Cell Mol Gastroenterol Hepatol. 10:491–506. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Mansoori B, Mohammadi A, Ditzel HJ, Duijf PHG, Khaze V, Gjerstorff MF and Baradaran B: HMGA2 as a critical regulator in cancer development. Genes (Basel). 12:2692021. View Article : Google Scholar : PubMed/NCBI
|
|
49
|
Zhang S, Mo Q and Wang X: Oncological role of HMGA2 (Review). Int J Oncol. 55:775–788. 2019.PubMed/NCBI
|
